Csk homologous kinase inhibits CXCL12-CXCR4 signaling in neuroblastoma

Abstract

Abstract. Neuroblastoma is the second most common pediatric malignancy. The clinical course of this disease ranges from spontaneous regression and good survival to highly malignant therapy-resistant tumors. There is a continuous need for genetic and biologic markers for the diverse clinical phenotypes observed in neuroblastoma patients. One of the known markers in neuroblastoma is expression of the CXCR4 chemokine receptor. CXCR4 expression correlates with high-stage disease, and the autocrine stimulation of CXCR4 by its ligand (CXCL12) was shown to be necessary for the survival of some neuroblastoma cells in vitro. However, the mechanisms responsible for activation of the CXCL12-CXCR4 autocrine pathway in neuroblastoma remain uncertain. Our previous findings suggest that Csk homologous kinase (CHK) is a physiological inhibitor of CXCR4 expression. Since CHK is highly expressed in neurons, we evaluated changes in CHK expression in human neuroblastoma. CHK protein expression was below detectable levels based on Western blot analyses in 13 out of 16 human neuroblastoma cell lines and in 6 out of 16 primary neuroblastoma tissues. When CHK expression was restored in IMR32 neuroblastoma cells by retrovirusmediated cDNA transfer, diminished CXCR4 mRNA and protein levels were observed, as assessed by RT-PCR and flow cytometry analyses, respectively. Furthermore, exogenous expression of CHK markedly suppressed the mRNA levels and secretion of the CXCL12 chemokine from IMR32 cells as well as inhibited the growth rate of these cells. Taken together, our data strongly suggest that CHK is capable of inhibiting the CXCL12-CXCR4 pathway in neuroblastoma.

CXCL12 (chemokine (C-X-C motif) ligand 12)

“…al., 2004;Zhang et al, 2008;Sun et al, 2010;Duda et al, 2011), pancreatic adenocarcinoma Wu et al, 2013), neuroblastoma (Zagozdzon et al,2008;Liberman et al, 2012), glioblastoma (Gatti et al, 2013;Wurth et al, 2014;Yao et al, 2015), colorectal cancer (Brand et al, 2005;Akishima-Fukasawa et al, 2009;Drury et al, 2010), melanoma (Scala et al, 2005;Toyozawa et al,2012;Mitchell et al, 2014), bladder cancer (Retz et al, 2005;, esophageal cancer (Sasaki et al, 2008;Wang et al, 2009;Tachezy et al, 2013), renal cancer (Pan et al, 2006;Ieran et al, 2014) and ovarian cancer (Popple et al, 2012).…”